Dysregulation of cytokines during graft-versus-host disease

Journal of Hematotherapy and Stem Cell Research

Volumn 5, Issue 1, 1996, Pages 3-14

  Krenger, Werner ^b   Ferrara, James L M ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 2; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; GRAFT VERSUS HOST REACTION; HELPER CELL; HUMAN; NONHUMAN; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ACUTE DISEASE; CHRONIC DISEASE; CYTOKINES; GRAFT VS HOST DISEASE; HUMANS; MODELS, BIOLOGICAL; NITRIC OXIDE; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 0029781474     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/scd.1.1996.5.3     Document Type: Article

References (136)

1. Marmont, A.M., Horowitz, M.M., Gale, R.P., et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 8:2120, 1991.
2. Martin, P.J. & Kernan, N.A. T-cell depletion for the prevention of graft-versus-host disease. In Graft-vs. Host Disease, eds. Burakoff, S.J., Deeg, H.J., Ferrara, J.L.M. & Atkinson, K. Marcel Dekker Inc., New York, 1985, p. 371.
3. Keever, C.A., Small, T.N., Flomenberg, N., et al. Immune reconstitution following bone marrow transplantation: Comparison of recipients of T-cell-depleted marrow with recipients of conventional marrow grafts. Blood 73:1340, 1989.
4. Poynton, C.H. T cell depletion in bone marrow transplantation. Bone Marrow Transplant. 3:265, 1988.
5. Ferrara, J.L.M. Cytokine dysregulation as a mechanism of graft-versus-host disease. Curr. Opin. Immunol. 5:794, 1993.
6. Antin, J.H. & Ferrara, J.L.M. Cytokine dysregulation and acute graft-versus-host disease. Blood 80:2964, 1992.
7. Jadus, M.R. & Wepsic, H.T. The role of cytokines in graft-versus-host reactions and disease. Bone Marrow Transplant. 10:1, 1992.
8. 2-incompatible transplanted SCID mice. Blood 83:2360, 1994.
9. Cavender, D.E., Haskard, D.O., Joseph, B., et al. Interleukin 1 increases the binding of human B and T lymphocytes to endothelial cell monolayers. J. Immunol. 136:203, 1986.
10. Thornhill, M.H., Wellicome, S.M., Mahiouz, D.L., et al. Tumor necrosis factor combines with IL-4 or IFN-γ to selectively enhance endothelial cell adhesiveness for T cells. J. Immunol. 146:592, 1991.
11. Pober, J.S., Gimbrone, M.A., Lapierre, L.A., et al. Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon. J. Immunol. 137:1893, 1986.
12. Chang, R.J. & Lee, S.H. Effects of interferon-γ and tumor necrosis factor-α on the expression of an Ia antigen on a murine macrophage cell line. J. Immunol. 137:2853, 1986.
13. Leeuwenberg, J.F., Van Damme, J., Maeger, T., et al. Effects of tumor necrosis factor on the interferon-γ-induced major histocompatibility complex class II antigen expression by human endothelial cells. Eur. J. Immunol. 18:1469, 1988.
14. Nestel, F.P., Price, K.S., Seemayer, T.A., et al. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor-α during graft-versus-host disease. J. Exp. Med. 175:405, 1992.
15. Ringden, O. Cyclosporine in allogeneic bone marrow transplantation. Transplantation 42:445, 1986.
16. Gluckman, E., Devergie, A., Lokiek, F., et al. Role of immunosuppressive drugs for prevention of graft-vs.-host disease after human HLA-matched bone marrow transplantation. Transplant. Proc. 19:61, 1987.
17. Via, C.S. Kinetics of T cell activation in acute and chronic forms of graft versus host disease. J. Immunol. 146:2603, 1991.
18. Garlisi, C.G., Pennline, K.J., Smith, S.R., et al. Cytokine gene expression in mice undergoing chronic graft-versus-host disease. Mol. Immunol. 30:669, 1993.
19. Theobald, M., Nierle, T., Bunjes, D., et al. Host-specific interleukin 2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. N. Engl. J. Med. 327:1613, 1992.
20. Schwarer, A.P., Jiang, Y.Z., Brookes, P.A., et al. Frequency of anti-recipient alloreactive helper T-cell precursors in donor blood and graft-versus-host disease after HLA-identical sibling bone-marrow transplantation. Lancet 341:203, 1993.
21. Nierle, T., Bunjes, D., Arnold, R., et al. Quantitative assessment of posttransplant host-specific interleukin 2-secreting T-helper cell precursors in patients with and without acute graft-versus-host disease after allogeneic HLA-identical sibling bone marrow transplantation. Blood 81:841, 1993.
22. Higuchi, C.M., Thompson, J.A., Petersen, F.B., et al. Toxicity and immunomodulatory effects of interleukin 2 after autologous bone marrow transplantation for hematologic malignancies. Blood 77:2561, 1991.
23. Jadus, M.R. & Peck, A.B. Lethal murine graft-versus-host disease in the absence of detectable cytotoxic T lymphocytes. Transplantation 36:281, 1983.
24. Chao, N.J. Cytokines. In Graft-Versus-Host Disease, ed. Chao, N.J. R.G. Landes Co, Austin, TX, 1994, p. 49.
25. Malkovsky, M., Brenner, M.K., Hunt, R., et al. T cell-depletion of allogeneic bone marrow prevents acceleration of graft-versus-host disease induced by exogenous interleukin 2. Cell Immunol. 103:476, 1986.
26. Ferrara, J.L.M., Marion, A., McIntyre, J.F., et al. Amelioration of acute graft-versus-host disease due to minor histocompatibility antigens by in vivo administration of anti-interleukin 2 receptor antibody. J. Immunol. 137:1784, 1986.
27. Herve, P., Wijdenes, J., Bergerat, J.P., et al. Treatment of corticosteroid-resistant acute graft-versus-host disease by in vivo administration of anti-interleukin 2 receptor monoclonal antibody (B-B10). Blood 75:1017, 1990.
28. Belanger, C., Esperou-Bourdeau, H., Bordigoni, P., et al. Use of an anti-interleukin 2 receptor monoclonal antibody for GVHD prophylaxis in unrelated donor BMT. Bone Marrow Transplant. 11:293, 1993.
29. Anasetti, C., Martin, P.M., Hansen, J.A., et al. A phase I-II study evaluating the murine anti-IL-2 receptor antibody 2 A3 for treatment of acute graft-versus-host disease. Transplantation 50:49, 1990.
30. Sykes, M., Romick, M.L., Hoyles, K.A., et al. In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment. J. Exp. Med. 171:645, 1990.
31. Sykes, M., Abraham, V.S., Harty, M.W., et al. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity. J. Immunol. 150:197, 1993.
32. Sykes, M., Harty, M.W., Szot, G.L., et al. Interleukin 2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects. Blood 83:2560, 1994.
33. Szebeni, J., Wang, M.G., Pearson, D.A., et al. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host disease. Transplantation 58:1385, 1994.
34. Soiffer, R.J., Murray, C., Cochran, K., et al. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin 2 after autologous and T-cell-depleted bone marrow transplantation. Blood 79:517, 1992.
35. Siegel, J.P. & Puri, R.K. Interleukin 2 toxicity. J. Clin. Oncol. 9:694, 1991.
36. Troutt, A.B. & Kelso, A. Enumeration of lymphokine mRNA-containing cells in vivo in a murine graft-versus-host reaction using the PCR. Proc. Natl. Acad. Sci. USA 89:5276, 1992.
37. Allen, R.D., Staley, T.A. & Sidman, C.L. Differential cytokine expression acute and chronic murine graft-versus-host disease. Eur. J. Immunol. 23:333, 1993.
38. Velardi, A., Varese, P., Terenzi, A., et al. Lymphokine production by T-cell clones after human bone marrow transplantation. Blood 74:1665, 1989.
39. Niederwieser, D., Herold, M., Woloszczuk, W., et al. Endogenous IFN-γ during human bone marrow transplantation. Transplantation 50:620, 1990.
40. Krenger, W., Snyder, K., Smith, S., et al. Effects of exogenous interleukin 10 in a murine model of graft-versus-host disease to minor histocompatibility antigens. Transplantation 58:1251, 1994.
41. Krenger, W., Snyder, K.M., Byon, C.H., et al. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease. J. Immunol. 155:585, 1995.
42. Wall, D.A., Hamberg, S.D., Reynolds, D.S., et al. Immunodeficiency in graft-versus-host reaction. I. Mechanism of immune separation. J. Immunol. 140:2970, 1988.
43. Dickinson, A.M., Sviland, L., Dunn, J., et al. Demonstration of direct involvement of cytokines in graft-versus-host reactions using an in vitro skin explant model. Bone Marrow Transplant. 7:209, 1991.
44. Wall, D. A. & Sheehan, K.C. The role of tumor necrosis factor-α and interferon-γ in graft-versus-host disease and related immunodeficiency. Transplantation 57:273, 1994.
45. Klimpel, G.R., Annable, C.R., Cleveland, M.G., et al. Immunosuppression and lymphoid hypoplasia associated with chronic graft-versus-host disease is dependent upon IFN-γ production. J. Immunol. 144:84, 1990.
46. Huchet, R., Bruley-Rosset, M., Mathiot, C., et al. Involvement of IFN-γ and transforming growth factor-β in graft-vs-host reaction-associated immunosuppression. J. Immunol. 150:2517, 1993.
47. Holda, J.H., Maier, T. & Claman, N.H. Evidence that IFN-γ is responsible for natural suppressor activity in GVHD spleen and normal bone marrow. Transplantation 45:772, 1988.
48. Hakim, F.T. & Shearer, G.M. Immunologic and hematopoietic deficiencies of graft-versus-host disease. In Graft-vs.-Host Disease, eds. Burakoff, S.J., Deeg, H.J., Ferrara, J.L.M. & Atkinson, K. Marcel Dekker, New York, 1990, p. 133.
49. Myers, J.D. Infection in bone marrow transplant recipients. Am. J. Med. 81:27, 1986.
50. Holda, J.H., Maier, T. & Claman, H.N. Natural suppressor activity in graft-vs-host spleen and normal bone marrow is augmented by IL-2 and interferon-γ. J. Immunol. 137:3538, 1986.
51. Rolink, A.G. & Gleichmann, E. Allosuppressor- and allohelper-T cells in acute and chronic graft-versus-host (GVH) disease. III. Different Lyt subsets of donor T cells induce different pathological syndromes. J. Exp. Med. 158:546, 1983.
52. Mowat, A. Antibodies to IFN-γ prevent immunological mediated intestinal damage in murine graft-versus-host reactions. Immunology 68:18, 1989.
53. Pace, J.L. & Russell, S.W. Activation of mouse macrophages for tumor cell killing. I. Quantitative analysis of interactions between lymphokine and lipopolysaccharide. J. Immunol. 126:1863, 1981.
54. Gifford, G.E. & Lohmann-Matthes, M.L. Gamma interferon priming of mouse and human macrophages for induction of tumor necrosis factor production by bacterial lipopolysaccharide. J. Natl. Cancer Inst. 78:121, 1987.
55. Mason, D.W., Dallman, M. & Barclay, A.N. Graft-versus-host disease induces expression of Ia antigen in rat epidermal cells and gut epithelium. Nature 293:150, 1981.
56. Huber, C. & Niederwieser, D. Role of cytokines and major histocompatibility complex antigens in graft-versus-host disease: In vitro studies using T cell lines and keratinocytes or hemopoietic targets. Haematol. Blood Trans. 33:652, 1990.
57. Brok, H.P.M., Heidt, P.J., van der Meide, P.H., et al. Interferon-γ prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice. J. Immunol. 151:6451, 1993.
58. Mowat, A.M. & Ferguson, A. Intraepithelial lymphocyte count and crypt hyperplasia measure the mucosal component of the graft-versus-host reaction in mouse small intestine. Gastroenterology 88:417, 1982.
59. Heremans, H., Dijkmans, R., Sobis, H., et al. Regulation by interferons of the local inflammatory response to lipopolysaccharide. J. Immunol. 138:4175, 1987.
60. Kuchroo, V.K., Martin, C.A., Greer, J.M., et al. Cytokines and adhesion molecules contribute to the ability of myelin proteolipid-specific T cell clones to mediate experimental allergic encephalomyelitis. J. Immunol. 151:4371, 1993.
61. Billiau, A., Heremans, H., Vendekerckhove, F., et al. Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-γ. J. Immunol. 140:1506, 1988.
62. Piguet, P.F., Grau, G.E., Allet, B., et al. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease. J. Exp. Med. 166:1280, 1987.
63. Mannel, D.N., Moore, R.N. & Mergenhagen, S.E. Macrophages as a source of tumoricidal activity (tumor necrotizing factor). Infect. Immunol. 30:523, 1980.
64. Beutler, B., Mahoney, J., Le Trang, N.P.P., et al. Purification of cachectin, a lipoprotein lipase-suppressing hormone by endotoxin-induced RAW 264.7 cells. J. Exp. Med. 161:984, 1985.
65. Nissen-Meyer, J. & Hammerstrom, J. Physicochemical characterization of cytostatic factors released from human monocytes. Infect. Immunol. 38:67, 1982.
66. Tracey, K.J. & Cerami, A. Tumor necrosis factor: Pleiotropic cytokine and therapeutic target. Annu. Rev. Med. 45:491, 1994.
67. Carswell, E.A., Old, L.J., Kassel, R.L., et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72:3666, 1975.
68. Long, N.C., Otterness, I., Kunkel, S., et al. Roles of interleukin 1β and tumor necrosis factor in lipopolysaccharide fever in rats. Am. J. Physiol. 259:724, 1990.
69. Dinarello, C.A., Cannon, J.G., Wolff, S.M., et al. Fever, tumor necrosis factor and interleukin 1. J. Exp. Med. 162:2163, 1986.
70. Tracey, K.J., Beutler, B., Lowry, S.F., et al. Shock and tissue injury induced by recombinant human cachectin. Science 234:470, 1986.
71. Piguet, P.F. Tumor necrosis factor and graft-versus-host disease. In Graft-vs. Host Disease, eds. Burakoff, S.J., Deeg, H.J., Ferrara, J.L.M. & Atkinson, K. Marcel Dekker Inc, New York, 1990, p. 258.
72. Piguet, P.F., Grau, G.E., Collart, M.A., et al. Pneumopathies of the graft-versus-host reaction. Alveolitis associated with an increased level of tumor necrosis factor mRNA and chronic interstitial pneumonitis. Lab. Invest. 61:37, 1989.
73. McCarthy, P.L., Abhyankar, S., Neben, S., et al. Inhibition of interleukin 1 by an interleukin 1 receptor antagonist prevents graft-versus-host disease. Blood 78:1915, 1991.
74. Porat, R., Clark, B.D., Wolfe, A.M., et al. Enhancement of growth of virulent Escherichia coli by interleukin 1. Science 254:431, 1991.
75. Ringden, O. Viral infections and graft-vs.-host disease. In Graft-vs.-Host Disease, eds. Burakoff, S.J., Deeg, H.J., Ferrara, J.L.M. & Atkinson, K. Marcel Dekker, New York, 1990, p. 467.
76. Clift, R.A., Buckner, C.D., Appelbaum, F.R., et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens. Blood 76:1867, 1990.
77. Gale, R.P., Bortin, M.M., van Bekkum, D.W., et al. Risk factors for acute graft-versus-host disease. Br. J. Haematol. 67:397, 1987.
78. Holler, E., Kolb, H.J., Hintermeier-Knabe, R., et al. The role of tumor necrosis factor-α in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation. Transplant. Proc. 25:1234, 1993.
79. Holler, E., Kolb, H.J., Moller, A., et al. Increased serum levels of tumor necrosis factor-a precede major complications of bone marrow transplantation. Blood 75:1011, 1990.
80. Herve, P., Flesch, M., Tiberghien, P., et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor-α antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 81:1993, 1992.
81. Dinarello, C.A. Interleukin 1 and interleukin 1 antagonism. Blood 77:1627, 1991.
82. Abhyankar, S., Gilliland, D.G. & Ferrara, J.L.M. Interleukin 1 is a critical effector molecule during cytokine dysregulation in graft-versus-host disease to minor histocompatibility antigens. Transplantation 53:1518, 1993.
83. Parkman, R., Lenarsky, C., Barrantes, B., et al. Cytokines versus cytotoxic T lymphocytes (CTL) in the pathogenesis of acute graft-versus-host disease (GVHD). J. Cell. Biochem. 16a:186, 1992.
84. Atkinson, K., Matias, C., Guiffre, A., et al. In vivo administration of granulocyte colony-stimulating (G-CSF), granulocyte-macrophage CSF, interleukin 1 (IL-1), and IL-4, alone and in combination, after allogeneic murine hematopoietic stem cell transplantation. Blood 77:1376, 1991.
85. Arend, W.P. Interleukin 1 receptor antagonist. Adv. Immunol. 54:167, 1993.
86. Arend, W.P., Joslin, F.G., Thompson, R.C., et al. An IL-1 inibitor from human monocytes. Production and characterization of biologic properties. J. Immunol. 143:1851, 1989.
87. Sullivan, K.M., Kopecky, K.J., Jocom, J., et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N. Engl. J. Med. 323:705, 1990.
88. Arend, W.P., Smith, J.M.F., Janson, R.W., et al., IL-1 receptor antagonist and IL-1β production in human monocytes are regulated differently. J. Immunol. 147:1530, 1991.
89. Nathan, C. & Xie, Q. Nitric oxide synthases: Roles, tolls and controls. Cell 78:915, 1994.
90. Stuehr, D.J. & Nathan, C.F. Nitric oxide: A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J. Exp. Med. 169:1543, 1989.
91. Garside, P., Hutton, A.K., Severn, A., et al. Nitric oxide mediates intestinal pathology in graft-vs-host disease. Eur. J. Immunol. 22:2141, 1992.
92. Langrehr, J.M., Murase, N., Markus, P.M., et al. Nitric oxide production in host-versus-graft and graft-versus-host reactions in the rat. J. Clin. Invest. 90:679, 1992.
93. Langrehr, J.M., Dull, K.E., Ochoa, J.B., et al. Evidence that nitric oxide production by in vivo allosensitized cells inhibits the development of allospecific CTL. Transplantation 53:632, 1992.
94. Hoffman, R.A., Langrehr, J.M., Billiar, T.R., et al. Alloantigen-induced activation of rat splenocytes is regulated by the oxidative metabolisms of L-arginine. J. Immunol. 145:2220, 1990.
95. Albina, J.E., Abat, J.A. & Henry, W.L. Nitric oxide production is required for murine resident peritoneal macrophages to suppress mitogen-stimulated T cell proliferation. Role of IFN-γ in the induction of then itric oxide synthesizing pathway. J. Immunol. 147:144, 1991.
96. Denham, S. & Rowland, I.J. Inhibition of the reactive proliferation of lymphocytes by activated macrophages: The role of nitric oxide. Clin. Exp. Immunol. 87:157, 1992.
97. Fu, Y. & Blankenhorn, E.P. Nitric oxide-induced anti-mitogenic effects in high and low responder rat strains. J. Immunol. 148:2217, 1992.
98. Langrehr, J.M., Hoffman, R.A., Lancaster, J.R. Jr., et al. Nitric oxide - A new endogenous immunomodulator. Transplantation 55:1205, 1993.
99. Angulo, I., Rodriguez, R., Garcia, B., et al. Involvement of nitric oxide in bone marrow-derived natural suppressor activity. Its dependence on IFN-γ. J. Immunol. 155:15, 1995.
100. Hoffman, R.A., Langrehr, J.M., Wren, S.M., et al. Characterization of the immunosuppressive effects of nitric oxide in graft vs host disease. J. Immunol. 151:1508, 1993.
101. Ding, A.M., Nathan, C.F. & Stuehr, D.J. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J. Immunol. 141:2407, 1988.
102. Drapier, J.C., Weitzerbin, J. & Hibbs, J.B. Interferon-γ and tumor necrosis factor induce the L-arginine-dependent cytotoxic effector mechanism in murine macrophages. Eur. J. Immunol. 18:1587, 1988.
103. Nussler, A.K., Di Silvio, M., Billiar, T.R., et al. Stimulation of the nitric oxide synthase pathway in human hepatocytes by cytokines and endotoxin. J. Exp. Med. 176:261, 1992.
104. Xie, K., Huang, S., Dong, Z., et al. Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J. Exp. Med. 181:1333, 1995.
105. Truitt, R.L., LeFever, A.V., Shih, C.C.Y., et al. Graft-vs.-leukemia effect. In Graft-vs.-Host Disease, eds. Burakoff, S.J., Deeg, H.J., Ferrarar, J.L.M. & Atkinson, K. Marcel Dekker Inc, New York, 1990, p. 177.
106. Drobyski, W.R., Keever, C.A., Hanson, G.A., et al. Inhibition of nitric oxide production is associated with enhanced weight loss, decreased survival, and impaired al-Ioengraftment in mice undergoing graft-versus-host disease after bone marrow transplantation. Blood 84:2363, 1994.
107. Mosmann, T.R., Cherwinski, H., Bond, M.W., et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136:2348, 1986.
108. Mosmann, T.R. & Coffman, R.L. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv. Immunol. 46:111, 1989.
109. Seder, R.A. & Paul, W.E. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu. Rev. Immunol. 21:635, 1994.
110. Del Prete, G., Maggi, E. & Romagnani, S. Human Th1 and Th2 cells: Functional properties, mechanisms of regulation, and role in disease. Lab. Invest. 70:299, 1994.
111. Croft, M., Carter, L., Swain, S.L., et al. Generation of antigen-specific CD8 effector populations: Reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J. Exp. Med. 180:1715, 1994.
112. Seder, R.A., Boulay, J.L., Finkelman, F.D., et al. CD8 T cells can be primed in vitro to produce IL-4. Immunology 148:1652, 1992.
113. Seder, R.A. The functional role of CD8+ T helper type 2 cells. J. Exp. Med. 181:5, 1995.
114. Le Gros, G. & Erard, F. Non-cytotoxic, IL-4, IL-5, IL-10 producing CD8+T cells: Their activation and-effector functions. Curr. Opin. Immunol. 6:453, 1994.
115. Kelso, A. Th1 and Th2 subsets: Paradigms lost? Immunol. Today 16:374, 1995.
116. Heinzel, F.P., Sadick, M.D., Holaday, B.J., et al. Reciprocal expression of interferon-γ or interleukin 4 during the resolution or progression of murine leishmaniasis. J. Exp. Med. 169:59, 1989.
117. Yamamura, J., Uyemura, K., Deans, R.J., et al. Defining protective responses to pathogens: Cytokine profiles in leprosy lesions. Science 254:277, 1991.
118. Gleichmann, E., Pals, S.T., Rolink, A.G., et al. Graft-versus-host reactions: Clues to the etiopathology of a spectrum of immunological diseases. Immunol. Today 5:324, 1984. 4
119. Via, C.S. & Finkelman, F.D. Critical role of interleukin 2 in the development of acute graft-versus-host disease. Int. Immunol. 5:565, 1993 .
120. Goldman, M., Druet, P. & Gleichmann, E. Th2 cells in systemic autoimmunity: Insights from allogeneic diseases and chemically induced autoimmunity. Immunol. Today 12:223, 1991.
121. De Wit, D., Van Mechelen, M., Zanin, C., et al. Preferential activation of Th2 cells in chronic graft-versus-host disease. J. Immunol. 150:361, 1993.
122. Doutrelepont, J.M., Moser, M., Leo, O., et al. HyperIgE in stimulatory graft-versus-host disease: role of interleukin 4. Clin. Exp. Immunol. 83:133, 1991.
123. Umland, S.P., Razac, S., Nahrebne, D.K., et al. Effects of in vivo administration of interferon (IFN)-γ, anti-IFN-γ, or anti-interleukin 4 monoclonal antibodies in chronic autoimmune graft-versus-host disease. Clin. Immunol. Immunopathol. 63:66, 1992.
124. Ushiyama, C., Hirano, T., Miyajima, H., et al. Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. J. Immunol. 154:2687, 1995.
125. Hsieh, C.S., Macatonia, S.E., Tripp, C.S., et al. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 260:547, 1993.
126. Manetti, R., Gerosa, F., Giudizi, M.G., et al. Interleukin 12 induces stable priming for interferon-γ (IFN-γ) production during differentiation of human T helper (Th) cells and transient IFN-γ production in established Th2 cell clones. J. Exp. Med. 179:11273, 1994.
127. Via, C.S., Rus, V., Gately, M.K., et al. IL-12 stimulates the development of acute graft-versus-host disease in mice that would normally develop chronic, autoimmune graft-versus-host disease. J. Immunol. 153:4040, 1994.
128. Rus, V., Svetic, A., Nguyen, P., et al. Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. J. Immunol. 155:2396, 1995.
129. Fowler, D.H., Kurasawa, K., Husebekk, A., et al. Cells of the Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction. J. Immunol. 152:1004, 1994.
130. Kuchroo, V.K., Das, M.P., Brown, J.A., et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80:707, 1995.
131. Henslee, P.J., Thompson, J.S., Romond, E.H., et al. T cell depletion of HLA and haploidentical marrow reduces graft-versus-host disease but it may impair a graft-versus-leukemia effect. Transplant. Proc. 19:2701, 1987.
132. Martin, P.J., Hansen, J.A., Torok-Storb, B., et al. Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant. 3:445, 1988.
133. Fowler, D.H., Kurasawa, K., Smith, R., et al. Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood 84:3540, 1994.
134. Sands, W.A., Bulut, V., Severn, A., et al. Inhibition of nitric oxide synthesis by interleukin 4 may involve inhibiting the activation of protein kinase C epsilon. Eur. J. Immunol. 24:2345, 1994.
135. Oswald, I.P., Gazzinelli, R.T., Sher, A., et al. IL-10 synergizes with IL-4 and transforming growth factor-β to inhibit macrophage cytotoxic activity. J. Immunol. 148:3578, 1992.
136. Liew, F.Y., Li, Y., Severn, A., et al. A possible novel pathway of regulation by murine T helper type 2 (Th2) cells of a Th1 cell activity via the modulation of the induction of nitric oxide synthase on macrophages. Eur. J. Immunol. 21:2489, 1991.